Perbedaan Rasio Trombosit Limfosit Pre dan Post Terapi Kemoradiasi Kanker Serviks di Rumah Sakit Pusat Angkatan Laut dr. Ramelan Surabaya
DOI:
https://doi.org/10.36452/jkdoktmeditek.v31i1.3105Keywords:
cervical cancer, chemoradiation therapy, platelet lymphocyte ratioAbstract
Introduction: Cervical cancer is caused by persistent infection with HPV transmitted through sexual intercourse. Chemoradiation is often used in the treatment of cervical cancer because it can reduce recurrence and further cell growth and can increase survival. Increased Platelet Lymphocyte Ratio (RTL) can be used to track the progression of cervical cancer and the degree of differentiation of cancer cells. High RTL indicates a worse degree of cell differentiation and vice versa. Purpose: The aim of this study was to determine the difference in RTL in cervical cancer patients pre and post chemoradiation therapy. Methods: The research design is cross-sectional with total sampling. Data was taken from medical records of cervical cancer patients at the Department of Obstetrics and Gynaecology, RSPAL dr. Ramelan Surabaya in year 2000 - 2023. Results: The average RTL for cervical cancer patients before chemoradiation was 193.1293; and after chemoradiation 169.5459. The results of the Wilcoxon signed rank test showed a significant decrease (p < 0.001). This research proves that there is a significant difference in the Platelet Lymphocyte Ratio (RTL) of stage ≥ IIB cervical cancer patients pre- and post-chemoradiation therapy. Statistical tests show significant results. Conclusion: Chemoradiation has been proven to significantly reduce RTL, and it can be concluded that giving chemoradiation to cervical cancer stage IIIB and above provides good results.
References
World Health Organization. Cervical cancer. 2022 [cited 2023 May 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
GLOBOCAN. Cancer today. 2020 [cited 2023 Jun 3]. Available from: https://gco.iarc.fr/today/online-analysis.
Kementerian Kesehatan Republik Indonesia. Wanita beresiko terkena kanker serviks. 2022 [cited 2023 Jun 3]. Available from: https://yankes.kemkes.go.id/view_artikel/389/wanita-beresiko-terkena-kanker-serviks.
Koh W, Abu-Rustum N, Bean S, Bradley K, Campos SM, Cho KR et al. Cervical cancer, version 3.2019. JNCCN J Natl Compr Canc Netw. 2019;17(1):64-84. DOI: 10.6004/jnccn.2019.0001
Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020:602-608. DOI: 10.1080/01443615.2019.1634030
Ashique S, Hussain A, Fatima N, Altamimi MA. HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. VirusDis. 2023;34(2):172-190. DOI: 10.1007/s13337-023-00824-z
Berek JS, Berek DL. Berek & Novak’s gynecology. 16th ed. Wolters Kluwer Health; 2020:1557-1589.
Chi D, Berduck A, Dizon D, Yashar C. Principles and practice of gynecology and oncology. 7th ed. Lippincott Williams & Wilkins, a Wolters Kluwer bu; 2017.
Sulistiya DP, Pramono D, Nurdiati D. Faktor-faktor yang berhubungan dengan kejadian kanker serviks di RSUP Dr. Sardjito Yogyakarta. Berita Kedokteran Masyarakat. 2017;33(3):125. doi: 10.22146/bkm.17160
Stumbar SE, Stevens M, Feld Z. Cervical cancer and its precursors: a preventative approach to screening, diagnosis, and management. Prim Care Clin Office Pract. 2019:117-134. DOI: 10.1016/j.pop.2018.10.011
Centers for Disease Control and Prevention. Cervical cancer. 2022 [cited 2023 Jun 1]. Available from: https://www.cdc.gov/cancer/cervical/basic_info/index.htm.
Kumar L, Harish P, Malik P, Khurana S. Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer. 2018;42(2):120-128. DOI: 10.1016/j.currproblcancer.2018.01.016
Prabawa IP, Bharghah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868. DOI: 10.31557/APJCP.2019.20.3.863
Anvari S, Osei E, Maftoom N. Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci Rep. 2021;11(1):15477. DOI: 10.1038/s41598-021-94735-y
Wang L, Jia J, Lin L, Guo J, Ye X, Zheng X, et al. Predictive value of hematological markers of systemic inflammation for managing cervical cancer. Oncotarget. 2017;8(27):44824-44832. doi: 10.18632/oncotarget.14827
Simadibrata D, Pandhita B, Ananta M, Tango T. Platelet-to-lymphocyte ratio, a novel biomarker to predict the severity of COVID-19 patients: a systematic review and meta-analysis. J Intensive Care Soc. 2022;23(1):20-26. doi: 10.1177/1751143720969587
Shofa GZ, Yuseran H, Hendriyono FX. Perbedaan rasio neutrofil limfosit kanker serviks tipe karsinoma sel skuamosa berdasarkan diferensiasi. Homeostasis. 2022;5(2):405. doi: 10.20527/ht.v5i2.6290
Haemmerle M, Stone R, Menter D, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965-983. DOI: 10.1016/j.ccell.2018.03.002
Sia J, Neeson PJ, Haynes NM. Basic cancer immunology for radiation oncologists. J Med Radiat Oncol. 2022;66(4):508-518. DOI: 10.1111/1754-9485.13406
Han X, Liu S, Yang G, Hosseinifard H, Imani S, Yang L, et al. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: a systematic review, meta-analysis, and meta-regression of observational studies. Gynecol Oncol. 2021;160(1):351-360. DOI: 10.1016/j.ygyno.2020.10.011
Hartono B, Pontih V, Merung Bagian M. Penilaian jumlah neutrofil, limfosit, dan trombosit, kadar protein reaktif C, kadar albumin, rasio neutrofil limfosit, serta rasio trombosit limfosit sebelum dan setelah terapi pada penderita karsinoma payudara. J Biomedik. 2015;7(3). Doi: 10.35790/jbm.7.3.2015.9487
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Purwo Diva Nadib Marbentan Marbentan, Ketut Edy Sudiarta, Diah Purwaningsari, Angela Puspita
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
